Perrigo Company PLC (PRGO)

14,980.00
+230.00(+1.56%)
  • Volume:
    139,725
  • Bid/Ask:
    14,960.00/14,980.00
  • Day's Range:
    14,810.00 - 14,980.00

PRGO Overview

Prev. Close
14,750
Day's Range
14,810 - 14,980
Revenue
15.46B
Open
14,900
52 wk Range
13,150 - 20,990
EPS
-
Volume
139,725
Market Cap
20.09B
Dividend (Yield)
313.55 (2.37%)
Average Vol. (3m)
114,800
P/E Ratio
-
Beta
-
1-Year Change
-21.38%
Shares Outstanding
-
Next Earnings Date
Aug 12, 2021
What is your sentiment on Perrigo Company PLC?
or
Vote to see community's results!

Perrigo Company PLC News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuySell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell

Perrigo Company PLC Company Profile

Perrigo Company PLC Company Profile

Sector
Services
Employees
11500

Perrigo Co. Plc engages in providing over-the-counter (OTC) self-care and wellness solutions. Its solutions enhance individual well-being by enabling consumers to proactively prevent or treat conditions that can be self-managed. The Company operates through three segments: Consumer Self-Care Americas, Consumer Self-Care International and Prescription Pharmaceuticals. The Consumer Self-Care Americas segment comprises the store brand consumer self-care business in the United States (U.S.), Mexico and Canada. The Consumer Self-Care International segment includes the branded consumer self-care business in Europe, along with generic consumer-focused businesses in the United Kingdom (U.K.) and Australia. The Prescription Pharmaceuticals segment commercializes and manufactures generic prescription products in the U.S. and diagnostic products in Israel.

Read More
  • February 27 Earnings call was terribly executed. The CEO was full of excuses as to why he is clueless on the future of the company. They missed earnings and could not give clear answers as the reasons. They demanded for their investors to wait until May 6 for guidance, as they do not know what they are going to do with the business. They only thing they would say is the product pricing is a headwind that will not end, they want to divest the Rx business but there are no buyers, and that they will continue to fight the tax dispute but can not make any claims about its possible outcome.
    0
    • he is just doing that he was joking around
      0
  • I'll be glad if it goes up to $85. Let's hope it will exceed analysts' expectations and maybe beat by a few cents. Cross your fingers pal!
    1
    • prgo had good Q1 2016 earning why she isnt at 130$ yet?
      0
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.